These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 29170024)

  • 1. Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors.
    Shadrick WR; Slavish PJ; Chai SC; Waddell B; Connelly M; Low JA; Tallant C; Young BM; Bharatham N; Knapp S; Boyd VA; Morfouace M; Roussel MF; Chen T; Lee RE; Kiplin Guy R; Shelat AA; Potter PM
    Bioorg Med Chem; 2018 Jan; 26(1):25-36. PubMed ID: 29170024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of ZA channel water-mediated interactions in the design of bromodomain-selective BET inhibitors.
    Bharatham N; Slavish PJ; Shadrick WR; Young BM; Shelat AA
    J Mol Graph Model; 2018 May; 81():197-210. PubMed ID: 29605436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and characterization of bromodomain 2-specific inhibitors of BRDT.
    Yu Z; Ku AF; Anglin JL; Sharma R; Ucisik MN; Faver JC; Li F; Nyshadham P; Simmons N; Sharma KL; Nagarajan S; Riehle K; Kaur G; Sankaran B; Storl-Desmond M; Palmer SS; Young DW; Kim C; Matzuk MM
    Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33637650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective inhibition mechanism of RVX-208 to the second bromodomain of bromo and extraterminal proteins: insight from microsecond molecular dynamics simulations.
    Wang Q; Li Y; Xu J; Wang Y; Leung EL; Liu L; Yao X
    Sci Rep; 2017 Aug; 7(1):8857. PubMed ID: 28821780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dihydropyridine Lactam Analogs Targeting BET Bromodomains.
    Jiang J; Sigua LH; Chan A; Kalra P; Pomerantz WCK; Schönbrunn E; Qi J; Georg GI
    ChemMedChem; 2022 Jan; 17(1):e202100407. PubMed ID: 34932262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of potent BET bromodomain 1 stereoselective inhibitors using DNA-encoded chemical library selections.
    Modukuri RK; Yu Z; Tan Z; Ta HM; Ucisik MN; Jin Z; Anglin JL; Sharma KL; Nyshadham P; Li F; Riehle K; Faver JC; Duong K; Nagarajan S; Simmons N; Palmer SS; Teng M; Young DW; Yi JS; Kim C; Matzuk MM
    Proc Natl Acad Sci U S A; 2022 May; 119(22):e2122506119. PubMed ID: 35622893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RVX-297- a novel BD2 selective inhibitor of BET bromodomains.
    Kharenko OA; Gesner EM; Patel RG; Norek K; White A; Fontano E; Suto RK; Young PR; McLure KG; Hansen HC
    Biochem Biophys Res Commun; 2016 Aug; 477(1):62-67. PubMed ID: 27282480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Solution structure of the second bromodomain of Brd2 and its specific interaction with acetylated histone tails.
    Huang H; Zhang J; Shen W; Wang X; Wu J; Wu J; Shi Y
    BMC Struct Biol; 2007 Sep; 7():57. PubMed ID: 17848202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
    Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
    Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric Cancer.
    Slavish PJ; Chi L; Yun MK; Tsurkan L; Martinez NE; Jonchere B; Chai SC; Connelly M; Waddell MB; Das S; Neale G; Li Z; Shadrick WR; Olsen RR; Freeman KW; Low JA; Price JE; Young BM; Bharatham N; Boyd VA; Yang J; Lee RE; Morfouace M; Roussel MF; Chen T; Savic D; Guy RK; White SW; Shelat AA; Potter PM
    Cancer Res; 2020 Sep; 80(17):3507-3518. PubMed ID: 32651255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of
    Sheppard GS; Wang L; Fidanze SD; Hasvold LA; Liu D; Pratt JK; Park CH; Longenecker K; Qiu W; Torrent M; Kovar PJ; Bui M; Faivre E; Huang X; Lin X; Wilcox D; Zhang L; Shen Y; Albert DH; Magoc TJ; Rajaraman G; Kati WM; McDaniel KF
    J Med Chem; 2020 May; 63(10):5585-5623. PubMed ID: 32324999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
    Chen D; Lu T; Yan Z; Lu W; Zhou F; Lyu X; Xu B; Jiang H; Chen K; Luo C; Zhao Y
    Eur J Med Chem; 2019 Nov; 182():111633. PubMed ID: 31461688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
    Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ
    J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DW71177: A novel [1,2,4]triazolo[4,3-a]quinoxaline-based potent and BD1-Selective BET inhibitor for the treatment of acute myeloid leukemia.
    Ali I; Cha HJ; Lim B; Chae CH; Youm J; Park WJ; Lee SH; Kim JH; Jeong D; Lim JK; Hwang YH; Roe JS; Woo JS; Lee K; Choi G
    Eur J Med Chem; 2024 Feb; 265():116052. PubMed ID: 38134745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress in the development of domain selective inhibitors of the bromo and extra terminal domain family (BET) proteins.
    Fu Y; Zhang Y; Sun H
    Eur J Med Chem; 2021 Dec; 226():113853. PubMed ID: 34547507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural investigation of a pyrano-1,3-oxazine derivative and the phenanthridinone core moiety against BRD2 bromodomains.
    Arole AH; Deshmukh P; Sridhar A; Padmanabhan B
    Acta Crystallogr F Struct Biol Commun; 2022 Mar; 78(Pt 3):119-127. PubMed ID: 35234137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Benzo[d]imidazole-6-sulfonamides as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain.
    Cipriano A; Milite C; Feoli A; Viviano M; Pepe G; Campiglia P; Sarno G; Picaud S; Imaide S; Makukhin N; Filippakopoulos P; Ciulli A; Castellano S; Sbardella G
    ChemMedChem; 2022 Oct; 17(20):e202200343. PubMed ID: 36040095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deciphering the mechanisms of selective inhibition for the tandem BD1/BD2 in the BET-bromodomain family.
    Cheng C; Diao H; Zhang F; Wang Y; Wang K; Wu R
    Phys Chem Chem Phys; 2017 Sep; 19(35):23934-23941. PubMed ID: 28849824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of the natural product 3',4',7,8-tetrahydroxyflavone as a novel and potent selective BRD4 bromodomain 2 inhibitor.
    Li J; Zou W; Yu K; Liu B; Liang W; Wang L; Lu Y; Jiang Z; Wang A; Zhu J
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):903-913. PubMed ID: 33820450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective N-Terminal BET Bromodomain Inhibitors by Targeting Non-Conserved Residues and Structured Water Displacement*.
    Cui H; Divakaran A; Pandey AK; Johnson JA; Zahid H; Hoell ZJ; Ellingson MO; Shi K; Aihara H; Harki DA; Pomerantz WCK
    Angew Chem Int Ed Engl; 2021 Jan; 60(3):1220-1226. PubMed ID: 32975004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.